Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2017 | Pages:
63 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Glycoprotein 41 (gp41) - Pipeline Review, H2 2017 Summary Glycoprotein 41 (gp41) - Gp41 or glycoprotein 41 is a transmembrane protein that contains several sites within its ectodomain that are required for infection of host cells. It is a subunit of the envelope protein complex of retroviruses. The interaction of gp41 fusion peptides with the target cell causes a formation of an intermediate structure which bridges and fuses the viral and host membranes together. Glycoprotein 41 (gp41) pipeline Target constitutes close to 19 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 6 and 2 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 5 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS). The latest report Glycoprotein 41 (gp41) - Pipeline Review, H2 2017, outlays comprehensive information on the Glycoprotein 41 (gp41) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics development with respective active and dormant or discontinued projects. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Glycoprotein 41 (gp41) - The report reviews Glycoprotein 41 (gp41) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics and enlists all their major and minor projects - The report assesses Glycoprotein 41 (gp41) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Glycoprotein 41 (gp41) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Glycoprotein 41 (gp41) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Glycoprotein 41 (gp41) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Glycoprotein 41 (gp41) - Overview 7 Glycoprotein 41 (gp41) - Therapeutics Development 8 Products under Development by Stage of Development 8 Products under Development by Therapy Area 9 Products under Development by Indication 10 Products under Development by Companies 11 Products under Development by Universities/Institutes 13 Glycoprotein 41 (gp41) - Therapeutics Assessment 15 Assessment by Mechanism of Action 15 Assessment by Route of Administration 16 Assessment by Molecule Type 18 Glycoprotein 41 (gp41) - Companies Involved in Therapeutics Development 20 Amunix Operating Inc 20 Frontier Biotechnologies Inc 20 InnaVirVax SA 21 Longevity Biotech Inc 21 Mymetics Corp 22 Navigen Inc 22 Osel Inc 23 Pharis Biotec GmbH 23 Glycoprotein 41 (gp41) - Drug Profiles 24 CPT-31 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 DS-007 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 Enfuvirtide-XTEN - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 FB-006M - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 HIV-1 vaccine - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 LBT-5001 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 Monoclonal Antibodies to Target GP120 and GP41 for HIV - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 MYMV-101 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 MYMV-201 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Recombinant Peptides for HIV-1 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Recombinant Protein to Inhibit Glycoprotein 41 and Glycoprotein 120 for Infectious Disease - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Small Molecules to Target GP120 and Gp41 for HIV-1 Infections - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 STOP-3S - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Synthetic Peptide to Target gp41 for HIV Infection - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Synthetic Peptides to Inhbit GP41 for HIV Infections - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 VAC-02 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 VAC-3S - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 VIR-576 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 Glycoprotein 41 (gp41) - Dormant Products 48 Glycoprotein 41 (gp41) - Discontinued Products 50 Glycoprotein 41 (gp41) - Product Development Milestones 51 Featured News & Press Releases 51 Sep 13, 2017: Mymetics to Present New Preclinical Data on Thermostable and Cold-Chain Independent Virosome based Vaccines 51 Oct 20, 2016: Dr. Michael Kay Presents Recent Data on Navigen's HIV Entry Inhibitor, CPT31, at the 2016 HIVR4P meeting 51 Sep 19, 2016: Mymetics and Texas Biomedical Research Institute Continue Collaboration on HIV Vaccine Development 52 Aug 24, 2016: Navigen Awarded $500,000 Grant to Support Depot Formulation of its HIV Drug Candidate 53 Jun 06, 2016: Frontier Biotech Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial 53 May 20, 2016: InnaVirVax Obtained FDA Authorization for a Phase 2 Clinical Trial with VAC-3S in HIV Functional Cure in the US 54 Apr 11, 2016: Mymetics' HIV vaccine candidate confirms promise in preclinical study with Texas Biomed 55 Jul 30, 2015: Encouraging results of the first clinical study of the VAC-3S vaccine against HIV, for which DIAXONHIT develops a companion diagnostic 56 Apr 30, 2015: Texas Biomed receives NIH grant to study papillomavirus-based AIDS vaccine 57 Oct 28, 2014: Amunix and PolyPeptide Enter Into Partnership to Produce XTEN Peptide Conjugates for Evaluation by Third Parties for Pharmaceutical Therapeutics 58 Jul 23, 2014: Amunix and PolyPeptide Publish Multivalent Antiviral XTEN-Peptide Conjugates in vivo Studies in American Chemical Society's Journal "Bioconjugate Chemistry" 58 Dec 01, 2013: InnaVirVax Initiates Phase 2 Clinical Trial Evaluating VAC-3S, A Therapeutic Vaccine Used in Combination With Standard Antiretroviral Therapy in Treatment of HIV-Infection 59 Mar 05, 2013: InnaVirVax Presents Results From Phase I/IIa Clinical Study Of VAC-3S At CROI 2013 60 Feb 21, 2013: Mymetics Announces Publication Of Positive Phase I Study Results Of HIV-1 Vaccine In PLOS ONE 60 Nov 30, 2012: InnaVirVax's HIV Vaccine VAC-3S Achieves Primary End Point In Phase I/IIa Study 61 Appendix 62 Methodology 62 Coverage 62 Secondary Research 62 Primary Research 62 Expert Panel Validation 62 Contact Us 62 Disclaimer 63
List of Tables
Number of Products under Development by Stage of Development, H2 2017 8 Number of Products under Development by Therapy Areas, H2 2017 9 Number of Products under Development by Indication, H2 2017 10 Number of Products under Development by Companies, H2 2017 11 Products under Development by Companies, H2 2017 12 Number of Products under Investigation by Universities/Institutes, H2 2017 13 Products under Investigation by Universities/Institutes, H2 2017 14 Number of Products by Stage and Mechanism of Actions, H2 2017 15 Number of Products by Stage and Route of Administration, H2 2017 17 Number of Products by Stage and Molecule Type, H2 2017 19 Pipeline by Amunix Operating Inc, H2 2017 20 Pipeline by Frontier Biotechnologies Inc, H2 2017 20 Pipeline by InnaVirVax SA, H2 2017 21 Pipeline by Longevity Biotech Inc, H2 2017 21 Pipeline by Mymetics Corp, H2 2017 22 Pipeline by Navigen Inc, H2 2017 22 Pipeline by Osel Inc, H2 2017 23 Pipeline by Pharis Biotec GmbH, H2 2017 23 Dormant Projects, H2 2017 48 Discontinued Products, H2 2017 50
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
